Solteq’s Q4 results were as expected weak and slightly below our estimates.
Finnair’s Q4 figures were slightly soft relative to estimates, however there were no big surprises.
Redeye comments on SDS’s Q4 results, which came in weaker than expected in terms of sales and profit...
EBITDA SEK 6m, vs. pre-announced SEK 6m & ABGSCe SEK 6m ARR SEK 120m, +14% y-o-y Significantly stren...
Redeye see a softer than anticipated Q4 report from Genovis which came in below expectations on both...
Marimekko’s Q4 net sales and adj. EBIT missed our estimates slightly yet the story continued to deve...
Redeye's first comments on the Q4 report this morning.
Redeye sees a Q4 report roughly matching our forecasts, with slightly lower guidance for 2024 relati...
NoHo Partners reported Q4 EBIT of EUR 10.6m, -5% versus Vara consensus and -6% versus our estimate.
Redeye notes that Sedana Medical’s Q4 report showed higher sales than our estimates, though EBITDA w...
Redeye comments on Embracers Q3-report where results where in line with expectations, albeit with so...
ExpreS2ion Biotechnologies inriktar resurserna på att ansöka om godkännande för att inleda en fas 1-...
Redeye comments on Sozap’s Q4 results, which showed higher sales figures than expected, primarily du...
Sales -3% vs. ABGSCe, adj. EBIT -28% vs. ABGSCe Drop in utilisation lowered sales by ~8% y-o-y alone...
Redeye updates on Invisio following the company’s Q4-results which were stronger than expected with ...
Redeye provides an update in relation to SenzaGen’s H2 2023 report.
Redeye retains its positive stance towards Hanza despite a somewhat softer Q4 report than expected, ...
Redeye comments on Thunderful Group’s preliminary Q4 numbers, which are significantly lower than our...
Earnings lift on better contract terms and cost savings 5% margin-driven EBITA upgrades for '24e-'25...
Redeye’s expectations for the fourth quarter were basically in-line with reported numbers.
